Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.23 -3.1%	$1.62	$1.20 ▼ $8.70	$19.96M	1.29	89,259 shs	36,438 shs
FENC Fennec Pharmaceuticals	$9.34 -2.4%	$10.09	$6.30 ▼ $11.92	$253.11M	0.38	111,209 shs	143,207 shs
GMDA Gamida Cell	$0.02	$0.24	$0.03 ▼ $2.51	$2.56M	0.93	9.20 million shs	1.72 million shs
XFOR X4 Pharmaceuticals	$1.26 +5.0%	$1.11	$0.57 ▼ $2.58	$211.60M	0.49	2.17 million shs	3.06 million shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	+0.79%	-7.97%	-15.33%	-42.27%	-83.07%
FENC Fennec Pharmaceuticals	-1.34%	-11.63%	-13.08%	-4.40%	+18.59%
GMDA Gamida Cell	-8.24%	+24.80%	-95.99%	-94.88%	-99.03%
XFOR X4 Pharmaceuticals	+0.42%	-2.83%	+23.61%	+59.70%	-14.29%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.0791 of 5 stars	3.5	3.0	0.0	0.6	0.0	0.6
FENC Fennec Pharmaceuticals	2.3659 of 5 stars	3.5	0.0	0.0	2.4	2.5	1.9
GMDA Gamida Cell	0.599 of 5 stars	3.4	2.0	0.0	0.0	0.8	0.0
XFOR X4 Pharmaceuticals	4.2672 of 5 stars	3.3	3.0	4.6	3.2	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.00	Buy	$19.80	1,509.76% Upside
FENC Fennec Pharmaceuticals	3.00	Buy	$17.33	85.58% Upside
GMDA Gamida Cell	2.75	Moderate Buy	$4.75	28,514.46% Upside
XFOR X4 Pharmaceuticals	2.50	Moderate Buy	$3.00	138.10% Upside

Current Analyst Ratings

Latest XFOR, FENC, APTO, and GMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2024	FENC Fennec Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
4/3/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$5.00
3/27/2024	APTO Aptose Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
3/22/2024	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
3/18/2024	FENC Fennec Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
3/18/2024	FENC Fennec Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$16.00
2/1/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $5.00
1/29/2024	GMDA Gamida Cell	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
FENC Fennec Pharmaceuticals	$21.25M	11.91	N/A	N/A	($0.43) per share	-21.72
GMDA Gamida Cell	$1.78M	1.43	N/A	N/A	($0.02) per share	-0.83
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	$0.31 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$7.72	N/A	N/A	N/A	N/A	-458.70%	-205.30%	5/13/2024 (Estimated)
FENC Fennec Pharmaceuticals	-$16.05M	-$0.61	N/A	13.34	N/A	-75.50%	N/A	-73.64%	5/9/2024 (Estimated)
GMDA Gamida Cell	-$63M	-$0.63	N/A	∞	N/A	N/A	N/A	-57.59%	5/20/2024 (Estimated)
XFOR X4 Pharmaceuticals	-$101.17M	-$0.60	N/A	N/A	N/A	N/A	-170.10%	-65.44%	5/2/2024 (Estimated)

Latest XFOR, FENC, APTO, and GMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/26/2024	Q4 2023	APTO Aptose Biosciences	-$1.48	-$1.44	+$0.04	-$1.44	N/A	N/A
3/21/2024	Q4 2023	FENC Fennec Pharmaceuticals	$0.02	-$0.10	-$0.12	-$0.10	$9.47 million	$9.74 million
3/21/2024	Q4 2023	XFOR X4 Pharmaceuticals	-$0.15	-$0.10	+$0.05	-$0.10	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
FENC Fennec Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMDA Gamida Cell	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	0.78	0.78
FENC Fennec Pharmaceuticals	N/A	3.56	3.27
GMDA Gamida Cell	213.14	2.16	2.09
XFOR X4 Pharmaceuticals	1.07	5.34	5.34

Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
FENC Fennec Pharmaceuticals	55.51%
GMDA Gamida Cell	50.34%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	9.53%
FENC Fennec Pharmaceuticals	11.25%
GMDA Gamida Cell	3.40%
XFOR X4 Pharmaceuticals	1.08%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	15.72 million	14.22 million	No Data
FENC Fennec Pharmaceuticals	N/A	27.10 million	24.06 million	Optionable
GMDA Gamida Cell	143	154.05 million	143.70 million	Optionable
XFOR X4 Pharmaceuticals	93	167.94 million	166.12 million	Optionable

XFOR, FENC, APTO, and GMDA Headlines

Source	Headline
	X4 Pharmaceuticals: PDUFA Excitement Ahead seekingalpha.com - April 18 at 12:45 AM
	X4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62 msn.com - April 17 at 7:45 PM
	X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns finance.yahoo.com - April 11 at 1:43 PM
	Research Analysts Issue Forecasts for X4 Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:XFOR) marketbeat.com - April 5 at 8:05 AM
	Brokers Set Expectations for X4 Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:XFOR) marketbeat.com - April 4 at 8:48 AM
	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) globenewswire.com - April 2 at 4:05 PM
	XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome… finance.yahoo.com - April 2 at 10:26 AM
	X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences globenewswire.com - April 1 at 8:00 AM
	X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript seekingalpha.com - March 23 at 3:45 PM
	Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects markets.businessinsider.com - March 22 at 5:16 PM
	X4 Pharmaceuticals (NASDAQ:XFOR) Given Buy Rating at HC Wainwright marketbeat.com - March 22 at 3:57 PM
	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript insidermonkey.com - March 22 at 3:06 PM
	Q4 2023 X4 Pharmaceuticals Inc Earnings Call finance.yahoo.com - March 22 at 2:14 AM
	XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023 investorplace.com - March 21 at 12:09 PM
	X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results finance.yahoo.com - March 21 at 10:08 AM
	X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update globenewswire.com - March 21 at 6:01 AM
	X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024 globenewswire.com - March 12 at 8:00 AM
	Arthur Taveras Sells 14,235 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock insidertrades.com - March 12 at 5:38 AM
	XFOR Jan 2026 1.000 call finance.yahoo.com - March 9 at 7:38 AM
	XFOR Apr 2024 1.500 call finance.yahoo.com - March 9 at 7:38 AM
	X4 Pharmaceuticals Inc (XFOR) investing.com - March 2 at 3:21 AM
	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) globenewswire.com - March 1 at 4:05 PM
	X4 Pharmaceuticals Stock (NASDAQ:XFOR), Short Interest Report benzinga.com - February 24 at 12:32 AM
	XFOR Mar 2024 1.500 put finance.yahoo.com - February 23 at 9:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptose Biosciences

NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Fennec Pharmaceuticals

NASDAQ:FENC

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Gamida Cell

NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

X4 Pharmaceuticals

NASDAQ:XFOR

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial